Market capitalization | CHF953.23m |
Enterprise Value | CHF1.01b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 29.85 |
EV/Sales (TTM) EV/Sales | 3.24 |
P/S ratio (TTM) P/S ratio | 3.07 |
P/B ratio (TTM) P/B ratio | 2.75 |
Revenue growth (TTM) Revenue growth | 13.27% |
Revenue (TTM) Revenue | CHF310.41m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a PolyPeptide forecast:
4 Analysts have issued a PolyPeptide forecast:
Jun '24 |
+/-
%
|
||
Revenue | 310 310 |
13%
13%
|
|
Gross Profit | 25 25 |
813%
813%
|
|
EBITDA | 12 12 |
215%
215%
|
EBIT (Operating Income) EBIT | -18 -18 |
56%
56%
|
Net Profit | -27 -27 |
24%
24%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.
Head office | Switzerland |
CEO | Juan-José Gonzalez |
Employees | 1,273 |
Founded | 1996 |
Website | www.polypeptide.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.